Eliminate weeks of cell culture while achieving superior sensitivity with reproducible results from INDIGO’s Expression Profiling of Clinically Relevant CYPs Utilizing upcyte Hepatocytes, 2×48 format.

• Kit includes optimized reagents for the culturing and treatment of upcyte® hepatocytes to assess drug-induced changes in CYP3A4, CYP1A1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1
• Exceptional cell viability post-thaw
• Consistent results lot to lot (product quality data available upon request)

This Expression Profiling of Clinically Relevant CYPs assay kit contains optimized reagents for the culturing and treatment of upcyte® hepatocytes to assess drug-induced changes in CYP3A4, CYP1A1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1.

The kit provides two aliquots of upcyte® hepatocytes, two cell culture-ready assay plates, optimized Cell Culture Medium for use in all steps of the assay procedure, and three reference compounds (rifampicin, β-naphthoflavone, and CDCA) that activate one or more of the primary xenobiotic-sensing receptors: PXR, CAR, AhR, and FXR. Upon activation, these nuclear receptors modulate the expression of the CYP genes. Also included are seven sets of validated qPCR primers for quantifying drug-induced changes in the expression of CYP3A4, CYP1A1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2E1, as well as primers for ACTB.

Please note: This kit does not include reagents or protocols for cell lysis, RNA isolation, cDNA preparation, or qPCR assays.